Geoff Kerchner, Md, Phd: Gantenerumab As Disease-Modifying Treatment In Early Alzheimer Disease

Geoff Kerchner, MD, PhD: Gantenerumab as Disease-Modifying Treatment in Early Alzheimer Disease

Geoff Kerchner, MD, PhD: Phase III Trials of Crenezumab in Treatment of Prodromal to Mild Alzheimer

Alzheimer’s Disease: The Latest Updates on Diagnosis and Treatment - Geoffrey Kerchner, MD, PhD

Alzheimer's Association California & Nevada

The Search for a Cure for Alzheimer's Disease: Geoffrey Kerchner, M.D., Ph.D.

Alzheimer's Association California & Nevada

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Assaulting Alzheimer's Disease | Geoffrey A. Kerchner | Talks at Google

Talks at Google

Important developments in dementia: biomarkers & clinical trials

Advances in Alzheimer's disease biomarkers & therapies

Question and Answer Discussion Geoffrey Kerchner and Ruth Gay

Alzheimer's Association California & Nevada

Gantenerumab data presented at CTAD- ADDF statement

Medical Dialogues

Rachelle Doody, MD, PhD: CREAD and GRADUATE trials for Alzheimer's

Gantenerumab in Early Alzheimer’s Disease | NEJM

Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab

Alzheimer's clinical trial drug yields negative result

“Aduhelm, Is This Medication Changing the Game for Alzheimer’s Disease?” Gregory Cooper, M.D., Ph.D.

Norton Healthcare

Second generation of anti-amyloid monoclonal antibodies for Alzheimer's disease

A Discussion of Treatments for Alzheimer's

Alzheimer's Association California & Nevada

Douglas Galasko, MD - Introducing Our Longitudinal Study

UCSD Shiley-Marcos ADRC

Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease